UK Biotechnology Conference
The second UK Biotechnology Ventures conference, which is organized bybusiness advisers Ernst & Young, will take place in London, UK, on March 20, 1997.
With the theme of challenges for emerging companies, the conference is aimed at existing and emerging companies that face the challenges of successfully developing an entrepreneurial bioscience venture. The meeting is supported by the UK's BioIndustry Association.
The conference organizers say that the rate of UK start-ups remains undiminished and there are a growing number of investors and funds with cash to finance well-planned and researched ventures. They see the forum as important to the sharing of knowledge and industry debate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze